Two-phase Partnering System Again Shows Decisive Superiority

 

Cascais, 7 March 2017. Two sunny conference days with extremely intense business negotiations at the Atlantic Ocean coast were an inspiring environment for almost 400 top business development executives of the global pharmaceutical industry. It came as a pleasant surprise to many who are used to ordinary partnering events with a handful of scheduled face-to-face meetings that euroPLX 63 Lisbon boasted an average of 30.5 one-on-one business negotiations for each of the 244 participating companies from 44 countries worldwide, or more than 23 meetings per attending person.

The unique combination of non-rejectable priority meeting requests with a subsequent accept-or-decline request phase to complete meeting schedules proves superior in every respect. This combination ensures that the scheduling of a delegate’s most important meeting requests - and customer’s satisfaction - is guaranteed while the less important requests are only scheduled if both parties agree.

The delegates’ partnering goals at euroPLX 63 Lisbon which has been held on 6 and 7 March 2017 in the scenic Portuguese town of Cascais near Lisbon, showed a clear preference for generic drugs (86%), although patented medicines (with 69%) are catching up at euroPLX while biosimilars gain steadily (28%), albeit from a low level. The interest was high across all therapeutic areas.